Recent News
Powered by Alpha Vantage
No recent news found.
AI Tools
Key Metrics
Trend: Downtrend
As of 2025-09-10 (Snapshot)
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing antiviral therapies for patients suffering from viral infections. The company is headquartered in Boston, Massachusetts.
52W High
$4.15
52W Low
$2.46
MA Status:
50D: Below
200D: Below
Beta (~1 neutral, <0.9 lower risk)
0.24
Valuation
As of 2025-06-30 (Overview)
Trailing P/E (<15 better)
N/A
Forward P/E (<15 better)
N/A
EV/EBITDA (<8 favorable)
-260.47
EV/Revenue (<3 favorable)
58.97
P/S (TTM) (<3 favorable)
1.90
P/B (<3 favorable)
0.73
Ownership
BalancedSource: Overview
Insiders (1–5% typical)
12.72%
Institutions (25–75% balanced)
71.90%
Shares Outstanding
79,358,000
Float
60,009,000
Dividend Yield (2–6% sweet spot)
N/A
Ex‑Dividend Date
N/A
Income & Growth
Profitability: Weak
As of 2025-06-30 (Overview)
Revenue (TTM)
192,180,000
Gross Profit (TTM)
-77,172,000
EPS (TTM)
-1.62
Profit Margin (>10% good)
N/A
Operating Margin (TTM) (higher better)
N/A
ROE (TTM) (>15% strong)
-0.32%
EPS YoY (Quarterly) (>10% good)
2.64
Revenue YoY (Quarterly) (>8% good)
2.95
Momentum
Bearish momentumValue
-0.0986
Previous
-0.1035
Trend
Rising
Signal Cross
No cross
As of
Sep. 11, 2025